A RANDOMIZED TRIAL OF 2 CISPLATIN-CONTAINING CHEMOTHERAPY REGIMENS IN PATIENTS WITH STAGE-III-B AND STAGE-IV NONSMALL CELL LUNG-CANCER

Seventy-four newly diagnosed patients with histologically proven Stage III-B and IV non-small cell lung cancer were randomized to receive either cisplatin: 20 mg/m(2) x day x 5, ifosfamide: 1.8 g/m(2) x day x 5, mesna: 1.2 g/m(2) x day x 5, etoposide: 100 mg/m(2) x day x 5 (ICE) or cisplatin: 20 g/m(2) x day x 5 and etoposide: 100 mg/m(2) x day x 5. Response rates were 59% in the ICE and 40% in the CE arm with a significant advantage in response duration and overall survival in the ICE receiving patients (P = 0.03, P = 0.0008). As we used granulocyte colony stimulating factor (G-CSF) very frequently, myelotoxicity remained substantial but acceptable.